NLRC4 and type 2 diabetes mellitus: Notably, ENB selectively targets NLRP3 without affecting other inflammasomes (e.g., AIM2, NLRC4).In multiple disease models—including LPS-induced systemic inflammation, MSU-induced peritonitis, and high-fat diet (HFD)-induced type 2 diabetes (T2D)—ENB exhibits potent anti-inflammatory and therapeutic effects (181).